NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Phase 3 Recruiting 200 enrolled Neurocrine Biosciences

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

Timeline

Start: 2025-05-30
Primary completion: 2027-07
Completion: 2027-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OSAVAMPATOR	Small molecule	—	Oral

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Summary

Timeline

Drugs

Indications